Loading
companiesCompany
Iovance Biotherapeutics
Iovance Biotherapeutics, of San Carlos, California, makes Amtagvi (lifileucel), the first approved tumour-infiltrating lymphocyte therapy, a treatment grown from a patient's own tumour-resident immune cells and approved in melanoma. Making it fast and cheap enough to reach most eligible patients is its open question.
Overview
Iovance Biotherapeutics, based in San Carlos, California, and listed as IOVA, makes Amtagvi, or lifileucel, the first approved tumour-infiltrating lymphocyte therapy. Lifileucel was approved in melanoma on the C-144-01 trial and in the European Union in 2025, TILVANCE-301 tests it in the first line, trials are running in lung and cervical cancer, and IOV-4001 is a next-generation PD-1-inactivated TIL product. OnCo links it to melanoma, to the TIL therapy technology, to the bottleneck of manufacturing cost and time for living medicines, and to ideas on selecting patients by whether their tumour holds reactive T cells. Whether TIL therapy can be made fast and cheap enough to reach most eligible patients is the open question. Lifileucel has its own page.
Headquarters
San Carlos, CA, US
Scorecard
All companies#94of 1244 companies, score 52
- approved products +12
- modalities +4
- regions +4
- 24-month regulatory events +2
- registry trials +30
2 approved, 0 in phase 3, 0 earlier, 0 targets, 360 registry studies. Formula on the scorecards page.
Type
Cell therapy · IOVA
Stage
Public
Website
ApprovedTIL cell therapy
Lifileucel · Amtagvi
Lifileucel was the first approved TIL therapy: the patient's own tumour-fighting immune cells are expanded to billions and given back.
ApprovedRecombinant interleukin-2 (cytokine)
Aldesleukin (high-dose IL-2) · Proleukin
High-dose interleukin-2 was the first immunotherapy to cure a small fraction of patients with metastatic melanoma and kidney cancer, at the cost of ICU-level toxicity; today it mainly supports TIL therapy.
Similar pages
- PersonAmod A. Sarnaik
Shares C-144-01, C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed, Lifileucel, TIL therapy.
- Key paperRohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma
Shares C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed, Aldesleukin (high-dose IL-2), Lifileucel, TIL therapy.
- PersonSteven A. Rosenberg
Shares C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed, Lifileucel, TIL therapy, Melanoma.
- PersonJohn Haanen
Shares Select patients for cell therapy by whether their tumour holds reactive T cells, Lifileucel, TIL therapy, Melanoma.
- PairingPD-1 failure → TIL therapy
Shares Lifileucel, TIL therapy, Melanoma.
- TreatmentTacquell (autologous melanoma-derived tumour-infiltrating lymphocytes)
Shares Lifileucel, TIL therapy, Melanoma.
- PersonInge Marie Svane
Shares Lifileucel, TIL therapy, Melanoma.
- TrialStudy of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Ca
Shares Aldesleukin (high-dose IL-2), TIL therapy, Melanoma.
cancers
fronts
technologies
drugs
ApprovedRecombinant interleukin-2 (cytokine)
Aldesleukin (high-dose IL-2) · Proleukin
ApprovedTIL cell therapy
Lifileucel · Amtagvi
trials
A Study of IOV-5001 in Adults With Advanced Solid TumorsA Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced MelanomaA Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung CancerA Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive LifileucelAutologous LN-145 in Patients With Metastatic Non-Small-Cell Lung CancerC-144-01Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.